Yarrow Bioscience, Inc. Common Stock (YARW)

Oct 07, 2026

A passive investor reports ownership of 1 million Yarrow Bioscience (YARW) shares. - Stock Titan

Oct 07, 2026

Sep 18, 2026

Raymond Debbane Reports 675,000 Shares in Yarrow Bioscience (NASDAQ: YARW) Representing 7.2% Passive Stake - Kalkine Media

Sep 18, 2026

Sep 17, 2026

New investor group tops 5% in Yarrow Bioscience (YARW) - Stock Titan

Sep 17, 2026

Sep 14, 2026

Yarrow Bioscience (NASDAQ: YARW) Grants Underwriters 30-Day Option for 865,384 Additional Shares - Kalkine Media

Sep 14, 2026

Sep 14, 2026

Yarrow Bioscience Raises About $161.8 Million in Public Stock Offering at $26 Per Share - TradingView

Sep 14, 2026

Sep 14, 2026

Yarrow Bioscience Files Prospectus for 25.78 Million Warrant-Linked Shares Offering (NASDAQ: YARW) - Kalkine Media

Sep 14, 2026

Sep 10, 2026

Yarrow Bioscience launches public offering of common stock - Investing.com India

Sep 10, 2026

Sep 10, 2026

Yarrow Bioscience Launches Public Offering of Common Stock - Yahoo Finance

Sep 10, 2026

Sep 10, 2026

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering - Business Wire

Sep 10, 2026

Sep 10, 2026

Yarrow Bioscience prices $150M public offering at $26/share - Investing.com

Sep 10, 2026

Sep 10, 2026

Yarrow Bioscience Announces Proposed Underwritten Public Offering - Business Wire

Sep 10, 2026

Aug 13, 2026

YARW SEC FilingsYarrow Bioscience, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Aug 13, 2026

Aug 13, 2026

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Aug 13, 2026

Aug 13, 2026

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire

Aug 13, 2026

Aug 13, 2026

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace

Aug 13, 2026

Aug 05, 2026

OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake - TradingView

Aug 05, 2026

Jul 30, 2026

Yarrow Bioscience Alters Capital Structure With Warrant Exchange - TipRanks

Jul 30, 2026

Jul 28, 2026

Yarrow Bioscience, Inc. (YARW) Company Information - Simply Wall Street

Jul 28, 2026

Jul 28, 2026

Yarrow Bioscience (Nasdaq:YARW)Stock Analysis - Simply Wall Street

Jul 28, 2026

Jul 28, 2026

Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut - TipRanks

Jul 28, 2026

Jul 27, 2026

Yarrow Bioscience Completes VYNE Merger and $200 Million Private Financing - citybiz

Jul 27, 2026

Jul 27, 2026

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Yahoo Finance

Jul 27, 2026

Jul 23, 2026

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - Yahoo Finance

Jul 23, 2026

Jul 22, 2026

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split, $17.3M Special Dividend, and Merger with Yarrow Bioscience – Minichart - Minichart

Jul 22, 2026

Jul 21, 2026

VYNE Sets $17.3M Cash Dividend Before Expected Yarrow Merger - Stock Titan

Jul 21, 2026

Jul 21, 2026

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - Yahoo Finance

Jul 21, 2026

Dec 17, 2025

VYNE Therapeutics and Yarrow Bioscience Announce Merger to Advance YB-101 for Graves' Disease and Thyroid Eye Disease - Quiver Quantitative

Dec 17, 2025

Dec 17, 2025

New biotech merger backs antibody targeting Graves’ and thyroid eye disease - Stock Titan

Dec 17, 2025